Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 4 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

Acetazolamide a promising treatment for sleep apnoea

25 Aug 2020

Short-term treatment with acetazolamide appears beneficial to patients with either central (CSA) or obstructive sleep apnoea (OSA), exerting favourable effects on the apnoea-hypopnoea index (AHI) and several patient-centred outcomes, including sleep quality and subjective symptoms, as shown in a study.

Researchers conducted a systematic review and meta-analysis of 28 studies evaluating the effect of oral acetazolamide in patients with OSA/CSA. About one-third of studies were conducted in Asia. In total, 542 patients were in the active treatment group and 553 were in the control group. Mean age ranged from 31 to 69 years, while mean body mass index varied between 21.9 and 38.3kg/m2.

Acetazolamide doses ranged from 36 to 1,000 mg/day, with treatment lasting between 1 and 90 days (median, 6 days). Compared with control, acetazolamide lowered the AHI overall by –0.7 effect sizes (95 percent confidence interval [CI], –0.83 to –0.58; I2, 0 percent; moderate quality of evidence), which corresponded to a reduction of 37.7 percent (95 percent CI, –44.7 to –31.3) or 13.8/h (95 percent CI, –16.3 to –11.4).

The AHI reduction was similar in OSA and CSA patients, but significantly greater with higher doses (at least up to 500 mg/day).

Notably, reductions in AHI were accompanied by improvements in SpO2 nadir (4.4 percent, 95 percent CI, 2.3–6.5; I2, 63 percent; no evidence of effect modification; very low quality of evidence) and several secondary outcomes including sleep quality measures and blood pressure (mostly low quality of evidence).

Based on the present data, the researchers pointed out that future studies may use acetazolamide at 125–500 mg/day (1–2 doses/day; evening dose 2 hours before bedtime) with close follow-up to rule out worsening of sleep apnoea. They added that it would take a few days to achieve the maximal effect for a given dose.

Common side effects, such as paraesthesia, were dose-dependent, so it would be practical to start with 3.5 mg/kg body weight or 125–250 mg/day and titrate up every 3–5 days as needed and tolerated, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 4 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.